Clearside Biomedical — Investor Presentation (November 2019)
33 slides from Clearside Biomedical's investor presentation, Nov 20, 2019
Slide 1: Corporate Presentation | November 2019
Corporate Presentation | November 2019 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”
Slide 3: Dedicated to Developing Treatments that Restore and Preserve Vision
Dedicated to Developing Treatments that Restore and Preserve Vision for People with Serious Eye Diseases Novel, therapeutic platform combines patented SCS Microinjector™ for Suprachoroidal Injection with proprietary drug formulations
Slide 4: Clearside Biomedical: Five Key Investment Themes
Clearside Biomedical: Five Key Investment Themes Proprietary access to the suprachoroidal space Patented technology and delivery approach Large and growing retinal market opportunity Partnering to monetize and expand use of SCS platform Building an internal R&D pipeline
Slide 5: Exclusive Access to the Back of the Eye Using Proprietary SCS Microinjector
© 2019 Clearside Biomedical, Inc. Exclusive Access to the Back of the Eye Using Clearside’s Proprietary SCS Microinjector™
Slide 6: Ocular Delivery Methods to Reach the Back of the Eye
Ocular Delivery Methods to Reach the Back of the Eye Suprachoroidal Space Injection Intravitreal Injection Broad diffusion to all areas of the eye including the anterior chamber and lens Highly variable drug diffusion across the sclera into the eye Periocular Injection Subretinal Injection Invasive
Slide 7: Strong Intellectual Property Coverage of SCS Platform
16 Apparatus using loss-of-resistance technology Administration of any anti-inflammatory drug to the suprachoroidal space by microinjection Methods of treating posterior ocular disorders including macular edema or uveitis Methods using loss-of-resistance technology Apparatus having / methods using a
Slide 8: Core Advantages of Treating Via the Suprachoroidal Space
Core Advantages of Treating Via the Suprachoroidal Space Sources: PK = pharmacokinetic | 1. Rai UDJ, Young SA, Thrimawithana TR, et al. The suprachoroidal pathway: a new drug delivery route to the back of the eye. Drug Discov Today. 2015;20(4):491-495. 3. Moisseiev E, Loewenstein A, Yiu G. The supra
Slide 9: Suprachoroidal Space & Triamcinolone Acetonide: Targeted for Efficacy
The Suprachoroidal Space & Triamcinolone Acetonide targeted for efficacy PreclinicalClinical Trial n=45 n=10 Percent subjects PEACHTREE Met its Primary Endpoint: Efficacy Data Subjects gaining ≥15 BCVA letters from baseline, % Source: Gilger, et al, Treatment of Acute Posterior Uveitis in a Porcine
Slide 10: Suprachoroidal Space & Triamcinolone Acetonide: Compartmentalized for Safety
The Suprachoroidal Space & Triamcinolone Acetonide compartmentalized for safety Values are area under the curve ratios (SCS / IVT) over 91 days in rabbit eyes 12 Sclera/Choroid/ Outer Retina 1 Neural Retina 0.03 Iris and Ciliary Body 0.002 Lens Drug not detected in the aqueous from SCS injection Pre
Slide 11: Suprachoroidal Space & Triamcinolone Acetonide: Prolonged PK for Durability
The Suprachoroidal Space & Triamcinolone Acetonide prolonged PK for durability PEACHTREE MAGNOLIA CLS-TA Injection #2 MAGNOLIA: Durability Data PreclinicalClinical Trial Sources: Gilger, et al, Treatment of Acute Posterior Uveitis in a Porcine Model by Injection of Triamcinolone Acetonide into the S
Slide 12: Two-Prong Corporate Strategy
Two-Prong Corporate Strategy Leveraging Clearside’s Proprietary Suprachoroidal Space (SCS) Injection Platform Grow our internal R&D pipeline Small molecules Gene therapy Create strategic external collaborations Commercialize lead asset Enable access to the SCS
Slide 13: Pipeline of SCS Treatments with Broad Applicability
STUDY DRUG INDICATION CLS-AX (suprachoroidal axitinib) Wet AMD Gene Therapy Inherited Retinal Disease Pipeline of SCS Treatments with Broad Applicability PRECLINICAL IND-Enabling PHASE 1/2 PHASE 3 NDA PARTNER INDICATION BAUSCH HEALTH XIPERE™ (macular edema associated with uveitis) AURA BIOSCIENCES O
Slide 14: Three Partnering Deals to Drive Growth
Three Partnering Deals to Drive Growth Eliminated the inherent risks and financial investment related to building and maintaining a commercial infrastructure Validated our investment in suprachoroidal delivery using our SCS Microinjector Eligible to receive >$200 million from the three partnerships
Slide 15: Maximizing Commercial Potential of XIPERE
The Opportunity: XIPERE Commercialization & Development Exclusive license for XIPERE commercialization and development in the U.S. and Canada Right to develop and commercialize XIPERE for additional ophthalmic indications including diabetic macular edema and retinal vein occlusion Right to develop a
Slide 16: Novel Approach to Targeting Uveitic Macular Edema
Pivotal Phase 3 PEACHTREE trial met its primary endpoint MAGNOLIA Phase 3 extension study demonstrated durability If approved, XIPERE would be the first therapy for this indication Expect to resubmit NDA in Q2 2020 with additional stability data and device use assessment Novel Approach to Targeting
Slide 17: Enabling In-office Delivery of Gene Therapy
The Opportunity: Gene Therapy Exclusive worldwide rights to our SCS Microinjector for delivery of adeno-associated virus (AAV)-based therapeutics to the suprachoroidal space to treat wet AMD, diabetic retinopathy and other conditions for which anti-VEGF treatment is the standard of care Delivery of
Slide 18: Optimizing Ocular Oncology Drug Delivery with SCS Microinjector
The Opportunity: Ocular Oncology Non-surgical alternative to intravitreal delivery of Aura’s oncology drug candidates via our SCS Microinjector Choroidal melanoma is the most common, primary intraocular tumor in adults Expect Aura to submit an IND amendment and initiate a clinical trial using our SC
Slide 19: Dr. Thomas Ciulla, Chief Medical Officer
Dr. Thomas Ciulla Chief Medical Officer
Slide 20: Broad Applicability of SCS Injection Platform: Small Molecules
Opportunity Concentrated distribution Protection of off-target tissues Migration of small molecules into the anterior chamber Extended duration of action Broad Applicability of SCS Injection Platform: Small Molecules Primary Need Targeted delivery to the retina with prolonged durability to enhance e
Slide 21: Axitinib for Suprachoroidal Injection (CLS-AX): Potential Solution for Treatment Burden
The Opportunity Pan-VEGF inhibition potentially more efficacious than current approaches Improve long-term, real-world visual outcomes for patients Reduce patient burden from monthly injections to every six months or longer Provide physicians with ability to titrate dose based on patient need Protec
Slide 22: CLS-AX Overview
INLYTA is a registered trademark of Pfizer, Inc. Items Details Target Patients For patients receiving frequent intravitreal anti-VEGF injections for neovascular AMD and diabetic macular edema Agent / Route of Administration Axitinib suspension for suprachoroidal injection Mechanism of Action Broadly
Slide 23: Suprachoroidal Axitinib May Improve Outcomes with Broad VEGF Blockade
AMD Vascular Endothelial Growth Factor Treatment Approaches Anti-VEGF-A increases VEGF-C 1 & VEGF-D2 Broad VEGF blockade may improve outcomes A Phase 2 study yielded better AMD outcomes with anti-VEGF-A,C,D vs anti-VEGF-A Current AMD Therapies Predominantly Focus on VEGF-A Blockade, not VEGF Recepto
Slide 24: CLS-AX May Address Unmet Needs in Neovascular AMD
CLS-AX May Address Unmet Needs in Neovascular AMD Sources: 1. Heier JS et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537-2548. | 2. Brown DM et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macu
Slide 25: CLS-AX: High Drug Levels Maintained in RPE-Choroid-Sclera
Concentration (nM) CLS-AX: High Drug Levels Maintained in RPE-Choroid-Sclera High Retina Levels: Sufficient to block VEGF pathway Low Plasma Levels: <1 ng/mL Time (days) Source: Based on non-clinical data 2.4 mg Drug remaining (mg) Time (days) Half-life > 3 months >60% remaining at 3 months
Slide 26: Topical Axitinib More Effectively Inhibited Corneal Neovascularization than Sunitinib and Sorafenib
Topical Axitinib More Effectively Inhibited Experimental Murine Corneal Neovascularization than Sunitinib and Sorafenib (same dose) Source: Yuan et al. Ocular Drug Delivery Nanowafer with Enhanced Therapeutic Efficacy. ACS Nano. 24 Feb 2015;9(2):1749-58
Slide 27: Potential to Disrupt the AMD Treatment Landscape
Potential to Disrupt the AMD Treatment Landscape Current Therapy Treatment burden Limited outcomes Ceiling of efficacy Focused VEGF Blockade Short Acting (1-3 months) CLS-AX Targeted for efficacy Compartmentalized for safety Biovailable with prolonged PK for durability Broad VEGF Blockade Long Actin
Slide 28: Broad Applicability of SCS Injection Platform: Ocular Gene Therapy
Opportunity Avoid risks of vitrectomy (surgery) Avoid risks of retinotomy, subretinal injection, and macular detachment Potential for broader retinal coverage Enhance patient access Convert gene therapy into an office-based procedure Broad Applicability of SCS Injection Platform: Ocular Gene Therapy
Slide 29: DNA Nanoparticle Gene Therapy and the Suprachoroidal Space
DNA Nanoparticle Gene Therapy and the Suprachoroidal Space Potential advantages: Efficacy: demonstrated in numerous ocular animal models Transfer large genes (up to ~20 kb) Safety: Non-immunogenic, without viral capsid proteins or pre-existing immunity. Potential for repeat dosing Higher doses possi
Slide 30: Preclinical SCS and Subretinal Injections of DNA Nanoparticles
Preclinical SCS and Subretinal Injections of DNA Nanoparticles Produced Comparable Luciferase Activity Source: Szilárd Kiss, MD, Macula Society Presentation February 2019 CHOROID-RPE-Sclera Non-Viral Luciferase, Rabbit RETINA Non-Viral Luciferase, Rabbit DNA Nanoparticles Transfect Choroid and Reti
Slide 31: Partnered Program: Viral Vectors Preclinical Activity
Source: Ding, K., Shen, J., Hafiz, Z., Hackett, S. F., Silva, R. L. E., Khan, M., ... Campochiaro, P. A. (2019). AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression. Journal of Clinical Investigation. doi: 10.1172/jci129085 Partnered Program: Viral Vectors Prec
Slide 32: Core Advantages of Treating Via the Suprachoroidal Space
Core Advantages of Treating Via the Suprachoroidal Space Sources: PK = pharmacokinetic | 1. Rai UDJ, Young SA, Thrimawithana TR, et al. The suprachoroidal pathway: a new drug delivery route to the back of the eye. Drug Discov Today. 2015;20(4):491-495. 3. Moisseiev E, Loewenstein A, Yiu G. The supra
Slide 33: UM Bane |
UM Bane |
Clearside Biomedical — Investor Presentation (November 2019) on 6ix